video still
Amgen
Amgen didn’t disrupt pharma — it proved that cloning one human gene at a time could build a billion-dollar company.
Chemistry
What things are made of and how they can be rearranged.
- 10
- in business
- 10:30
- average
- 105 min
- in total
- 83
- across the network
All briefs
video still
AstraZeneca
AstraZeneca is not a British company — it is a 1999 merger with no disclosed financials, no stated cost model, and no evidence of how it actually delivers value beyond its own description.
video still
Bristol Myers Squibb
A 1989 merger of two penicillin-makers became a US-revenue monoculture built on seven drugs — not science, but scale.
video still
Norsk Hydro
Kristian Birkeland · 1905
Norsk Hydro began as a single-purpose vehicle for Birkeland’s nitrogen-fixing arc — a physics experiment turned factory. Its early dominance came not from IP or management, but from locking in Norway’s hydropower geography. It survived obsolescence not through reinvention, but by ceding chemical control to IG Farben. Its WWII role — sole European heavy water producer — was accidental infrastructure reuse. Its current aluminium and renewables business shares no technology with its origin, only its dams, debt, and place.
video still
Pfizer
Charles Pfizer · 1849
Pfizer’s origin story is not about curing disease — it is about solving chemical supply problems with fermentation. Its therapeutic dominance came decades after it mastered industrial microbiology under pressure.
video still
BASF
BASF isn’t a legacy—it’s a rebranding of catastrophe.
video still
Bayer
Friedrich Bayer · 1863
Bayer was a dyestuffs partnership founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott. It expanded through synthetic dye innovation, relocated due to arsenic contamination, built brand equity via Aspirin and the Bayer Cross, then merged into IG Farben in 1925 — whose assets were seized post-WWII for Nazi atrocities.
video still
Novartis
A merger born of necessity, not vision — Novartis was built to survive, not invent.
video still
Roche
Roche isn’t a biotech pioneer — it’s a precision acquirer that turns diagnostics and drugs into a single revenue stream.
video still
SK Group
Chey Jong-hyon · 1953
SK Group is a South Korean chaebol founded in 1953 through the acquisition of Sunkyong Textiles — Japanese-owned property seized by the South Korean government after the Korean War armistice. It is the second-largest chaebol by revenue, controlled by the estate of Chey Tae-won via SK Inc., and operates 186 subsidiaries under the SKMS management system. Its cornerstone remains energy and chemicals, though it spans AI semiconductors, flash memory, telecommunications, and petrochemicals. The material confirms no revenue figures, margins, valuations, or operational metrics beyond structure, origin, control, and sectoral scope.